ReviewThe Lancet. Microbe2026
Global perspective on gaps in fungal diagnostics in low-resource settings: WHO landscape analysis and research priorities for invasive fungal diseases.
Review in The Lancet. Microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Review of the Therapeutic Challenges and Novel Treatment Options in Mitigating Invasive Mycosis Associated withJournal of fungi (Basel, Switzerland) · 2026Review
- Evaluation of Molecular Assays for Rapid Diagnosis of Invasive Fungal Infections: Clinical Experience with the Commercial CandID and AspID Real-Time PCR Assays in Paraguay.Journal of fungi (Basel, Switzerland) · 2026Article
- Neutrophil extracellular traps in antifungal immunity: mechanisms, dual roles, regulatory networks, and clinical perspectives.Frontiers in cellular and infection microbiology · 2026Review
- Operationalizing the WHO Blueprint for Fungal Disease and Antifungal Resistance in Fragile Health Systems: Insights from Somalia.Infection and drug resistance · 2026Article
- Advanced Eumycetoma of the Right Foot Resulting in Below-Knee Amputation in Somalia: A Case Report.International medical case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal diseases (IFDs) are a growing global health threat, particularly in low-income and middle-income countries (LMICs), where diagnostic capacity is limited. The emergence and spread of antifungal resistance further complicate clinical management. Despite the high burden of IFDs, diagnostic development for fungal pathogens has lagged compared with that for its bacterial and viral counterparts. In this Review, we synthesised findings from WHO's 2024 diagnostic landscape analysis of fungal priority pathogens. We discussed the availability, accessibility, and performance of the current diagnostic tools, including phenotypic, immunological, and molecular methods, and identified key gaps in LMICs. WHO's research and development priorities for diagnostics for LMICs are also presented herein. The assessment reveals that most diagnostic platforms for IFDs are culture dependent, infrastructure intensive, and inaccessible at primary and secondary health-care levels in LMICs. Non-culture-based methods, such as lateral flow immunoassays and molecular diagnostics, are promising, but remain restricted in scope, species coverage, and affordability. Multiplex platforms capable of simultaneous broad pathogen detection and antifungal resistance testing are scarce. WHO has identified priority areas for diagnostic innovation, including simplified lateral flow immunoassays, automated culture systems, and integrated molecular platforms suitable for use in LMICs. Addressing diagnostic gaps for IFDs requires targeted investment in simplified, rapid, and affordable diagnostic tools that can be deployed across multiple levels of health-care system. WHO's research and development priorities aim to guide diagnostic developers and public health stakeholders in accelerating innovation and improving access to fungal diagnostics, particularly in LMICs, to reduce IFD-related morbidity and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.